John A Pugliese1, Garen J Wintemute2, Stephen G Henry3. 1. Safe and Active Communities Branch, California Department of Public Health, Sacramento, California. Electronic address: john.pugliese@cdph.ca.gov. 2. Department of Emergency Medicine, University of California, Davis Medical Center, Sacramento, California. 3. Division of General Medicine, Geriatrics, and Bioethics, University of California, Davis Medical Center, Sacramento, California.
Abstract
INTRODUCTION: The purpose of this study is to extend prior research on barriers to use of a prescription drug monitoring program by examining psychosocial correlates of intended use among physicians and pharmacists. METHODS: Overall, 1,904 California physicians and pharmacists responded to a statewide survey (24.1% response rate) from August 2016 to January 2017. Participants completed an online survey examining attitudes toward prescription drug misuse and abuse, prescribing practices, prescription drug monitoring program design and ease of use, professional obligations, and normative beliefs regarding prescription drug monitoring program use. Data were analyzed in 2017. RESULTS: Perceived prescription drug monitoring program usefulness and normative beliefs fully mediated the relationship between concern about prescription drug abuse and intentions to use the prescription drug monitoring program. Clinicians' sense of professional and moral obligation to use the prescription drug monitoring program was unrelated to intention to use the prescription drug monitoring program despite a positive relationship with concern about misuse and abuse. Compared with physicians, pharmacists reported greater concern about prescription drug misuse, greater professional and moral obligation to use prescription drug monitoring program, and greater rating of prescription drug monitoring program usefulness. CONCLUSIONS: Interventions that target normative beliefs surrounding prescription drug monitoring program use and how to use prescription drug monitoring programs effectively are likely to be more effective than those that target professional obligations or moralize to the medical community. Published by Elsevier Inc.
INTRODUCTION: The purpose of this study is to extend prior research on barriers to use of a prescription drug monitoring program by examining psychosocial correlates of intended use among physicians and pharmacists. METHODS: Overall, 1,904 California physicians and pharmacists responded to a statewide survey (24.1% response rate) from August 2016 to January 2017. Participants completed an online survey examining attitudes toward prescription drug misuse and abuse, prescribing practices, prescription drug monitoring program design and ease of use, professional obligations, and normative beliefs regarding prescription drug monitoring program use. Data were analyzed in 2017. RESULTS: Perceived prescription drug monitoring program usefulness and normative beliefs fully mediated the relationship between concern about prescription drug abuse and intentions to use the prescription drug monitoring program. Clinicians' sense of professional and moral obligation to use the prescription drug monitoring program was unrelated to intention to use the prescription drug monitoring program despite a positive relationship with concern about misuse and abuse. Compared with physicians, pharmacists reported greater concern about prescription drug misuse, greater professional and moral obligation to use prescription drug monitoring program, and greater rating of prescription drug monitoring program usefulness. CONCLUSIONS: Interventions that target normative beliefs surrounding prescription drug monitoring program use and how to use prescription drug monitoring programs effectively are likely to be more effective than those that target professional obligations or moralize to the medical community. Published by Elsevier Inc.
Authors: Traci C Green; Marita R Mann; Sarah E Bowman; Nickolas Zaller; Xaviel Soto; John Gadea; Catherine Cordy; Patrick Kelly; Peter D Friedmann Journal: Pain Med Date: 2012-07-30 Impact factor: 3.750
Authors: Marc L Fleming; Jamie C Barner; Carolyn M Brown; Marvin D Shepherd; Scott Strassels; Suzanne Novak Journal: Res Social Adm Pharm Date: 2013-06-29
Authors: Amie J Goodin; Joshua D Brown; Chris Delcher; Patricia R Freeman; Jeffery Talbert; Stephen G Henry; Dikea Roussos-Ross Journal: Res Social Adm Pharm Date: 2019-03-26
Authors: Alysia Robinson; Maria N Wilson; Jill A Hayden; Emily Rhodes; Samuel Campbell; Peter MacDougall; Mark Asbridge Journal: Pain Med Date: 2021-07-25 Impact factor: 3.750